ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IRON Disc Medicine Inc

58.97
1.14 (1.97%)
Last Updated: 16:34:40
Delayed by 15 minutes
Share Name Share Symbol Market Type
Disc Medicine Inc NASDAQ:IRON NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.14 1.97% 58.97 58.42 58.96 61.08 58.09 59.11 70,235 16:34:40

Disc Medicine to Participate in Upcoming Investor Conferences

30/08/2024 1:00pm

GlobeNewswire Inc.


Disc Medicine (NASDAQ:IRON)
Historical Stock Chart


From Jul 2024 to Jan 2025

Click Here for more Disc Medicine Charts.

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:

  • 2024 Wells Fargo Securities Healthcare Conference on Friday, September 6th at 10:15 a.m. ET.
  • Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6th at 1:05 p.m. ET.
  • H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11th at 9:30 a.m. ET.
  • 2024 Cantor Global Healthcare Conference on Thursday, September 19th at 8:00 a.m. ET.

A live webcast of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg RusconiDeerfield Grouppeg.rusconi@deerfieldgroup.com

Investor Relations Contact

Christina TartagliaPrecision AQ christina.tartaglia@precisionaq.com

1 Year Disc Medicine Chart

1 Year Disc Medicine Chart

1 Month Disc Medicine Chart

1 Month Disc Medicine Chart

Your Recent History

Delayed Upgrade Clock